Back to Dashboard
CAPR · Healthcare

CAPRICOR THERAPEUTICS INC

USA Healthcare Filing: 2025-12-31
Smart-money confidence · 1 of 3 sources firing
Bearish — money moving out

No standout activity across the feeds we track.

Hedge funds
20
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
◆ Next steps Interested in CAPRICOR THERAPEUTICS INC? Here's what to do with it.
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$405M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About CAPRICOR THERAPEUTICS INC

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered…

Who's behind the signal
Every informed buyer we can see on CAPR, across all three feeds.
Hedge funds · 4
Point72 (Steve Cohen) Increased +1451%
Citadel Advisors Increased +499%
AQR Capital Management Decreased −30%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar. CAPRICOR THERAPEUTICS INC isn't in the top-10 model right now, but 4 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
4
Investors
0
New positions
3
Increasing
1
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
Increased +1451%
% of portfolio
0.1%
Position change
+1451%
0.1% of Point72's portfolio
Trust weight: 1.0×
Increased +499%
% of portfolio
0.0%
Position change
+499%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
Increased +237%
% of portfolio
0.0%
Position change
+237%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
Decreased −30%
% of portfolio
0.0%
Position change
−30%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to CAPRICOR THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell CAPRICOR THERAPEUTICS INC or any security.

Get the Weekly Update

Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime